This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
past and present members of the STAMPEDE and FOCUS4 Trial Management Group
MetadataShow full item record
BACKGROUND: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes. METHODS: We evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation. RESULTS: Specific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials. Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges. CONCLUSIONS: Understanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective. TRIAL REGISTRATION: FOCUS4: ISRCTN Registry, ISRCTN90061546 . Registered on 16 October 2013. STAMPEDE: ISRCTN Registry, ISRCTN78818544 . Registered on 2 February 2004.
Version of record
Multi-arm multi stage
License start date
Trials, 2019, 20 (1), pp. 264 - ?
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Randomized trial of porcarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial Thomas, D; Brada, M; Stenning, S; Work, MRCBT (2001-01-15)Purpose: Meta-analyses of the published literature suggest ct survival benefit to adjuvant chemotherapy for high-grade astrocytoma, which individual sma trials have been unable to demonstrate reliably. The Medical Research ...
Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. Wilkins, A; Stuttle, C; Hassan, S; Blanchard, C; Cruickshank, C; Griffin, C; Probert, J; Corbishley, CM; Parker, C; Dearnaley, D; Hall, E (2018-03)Background: This article presents the methodology for tissue sample collection in Trans-CHHiP, the main translational study within the CHHiP (Conventional or Hypofractionated High dose intensity modulated radiotherapy in ...
Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit Murad, MH; Guyatt, GH; Domecq, JP; Vernooij, RWM; Erwin, PJ; Meerpohl, JJ; Prutsky, GJ; Akl, EA; Mueller, K; Bassler, D; Schandelmaier, S; Walter, SD; Busse, JW; Kasenda, B; Pagano, G; Pardo-Hernandez, H; Montori, VM; Wang, Z; Briel, M (Elsevier BV, 2017-02)